Pfizer CEO Bourla Hands AI Decisions to Business Unit Heads After Slow Two-Year Rollout
Pfizer is restructuring how it runs artificial intelligence, shifting decisions from a central team of specialists to the business leaders closest to each domain. CEO Albert Bourla told the Wall Street Journal's CEO Brief that the change reverses his earlier approach, which he said had stalled. He described progress under the old model as "stagnation," despite two years of enterprise-wide AI integration. Under the new setup, domain leaders make the AI calls and are accountable for how workflows and operations change, while a central team provides support. Bourla says the move reduced internal resistance and sped adoption, and reporting describes cross-functional groups called "clans" that link departments. The story was reported October 9, 2026.